Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation

Korean Journal of Radiology

Volumn 8, Issue 4, 2007, Pages 320-327

  Ko, Heung Kyu ^a   Ko, Gi Young ^b   Hyun, Ki Yoon ^b   Sung, Kyu Bo ^b,c  

^a Yonsei University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c University of Ulsan   (South Korea)

Author keywords

Chemoembolization; Hepatocellular carcinoma; Liver transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CONTRAST MEDIUM; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; LIVING DONOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; SURVIVAL RATE; TUMOR RECURRENCE; VASCULARIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODIZED OIL; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE;

EID: 34548240598     PISSN: 12296929     EISSN: None     Source Type: Journal    
DOI: 10.3348/kjr.2007.8.4.320     Document Type: Article

References (22)

1. Kaihara S, Kiuchi T, Ueda M, Oike F, Fujimoto Y, Ogawa K, et al. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 2003;75:S37-40
2. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127:S277-282
3. O'Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 1988;207:373-379
4. Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991;15:270-285
5. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-151
6. Tan KC, Rela M, Ryder SD, Rizzi PM, Karani J, Portmann B, et al. Experience of orthotopic liver transplantation and hepatic resection for hepatocellular carcinoma of less than 8 cm in patients with cirrhosis. Br J Surg 1995;82:253-256
7. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004;240:451-459; discussion 459-461
8. Gondolesi GE, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein TM, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004;239:142-149
9. Regalia E, Fassati LR, Valente U, Pulvirenti A, Damilano I, Dardano G, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 1998;5:29-34
10. Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 2005;43:584-589
11. Margarit C, Charco R, Hidalgo E, Allende H, Castells L, Bilbao I. Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg 2002;26:257-263
12. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699
13. Atiq OT, Kemeny N, Niedzwiecki D, Botet J. Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. Cancer 1992;69:920-924
14. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442
15. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917
16. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-188
17. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, Amesur N, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003;97:1042-1050
18. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534-540
19. Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991;68:2095-2100
20. Steininger R, Herbst F, Fugger R, Muhlbacher F, Fritsch A. Immunosuppression does not enhance tumor growth after orthotopic liver transplantation for hepatoma. Transplant Proc 1992;24:2690-2692
21. Ishii H, Furuse J, Kinoshita T, Konishi M, Nakagohri T, Takahashi S, et al. Extrahepatic spread from hepatocellular carcinoma: who are candidates for aggressive anti-cancer treatment? Jpn J Clin Oncol 2004;34:733-739
22. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-1991